What is Sciessent?
Sciessent operates at the intersection of chemical engineering and consumer product performance, providing essential technologies that enhance the functionality of textiles, medical devices, and industrial surfaces. The company's core value proposition lies in its ability to integrate anti-odor, water-repellent, and antimicrobial properties into diverse substrates, thereby extending product lifecycles and improving user experiences. By serving high-demand markets such as healthcare and performance apparel, Sciessent has established itself as a critical partner for manufacturers seeking to differentiate their offerings through advanced material science. Their technical expertise and commitment to rigorous testing protocols ensure that their solutions meet the stringent requirements of both regulatory bodies and end-consumers, cementing their status as a leader in the specialty chemicals space.
How much funding has Sciessent raised?
Sciessent has raised a total of $3.4M across 2 funding rounds:
Private Equity
$3M
Debt
$350K
Private Equity (2005): $3M with participation from H.B. Fuller Ventures and BASF Venture Capital
Debt (2020): $350K led by PPP
Key Investors in Sciessent
H.B. Fuller Ventures
H.B. Fuller is a global leader in adhesives and specialty chemicals, focusing on innovation and technical expertise to solve complex manufacturing challenges across diverse industrial markets.
BASF Venture Capital
The corporate venture capital arm of BASF Group, this firm invests in high-growth startups that align with their strategic interests in circular economy, new materials, and biotechnology.
PPP
Public-Private Partnership
What's next for Sciessent?
Looking ahead, Sciessent is poised to leverage its recent capital injection to expand its footprint in the circular economy and sustainable materials market. The strategic focus will likely shift toward optimizing supply chain resilience and scaling the production of its NOBO 88 technology to meet rising global demand for high-performance surfaces. As the company transitions into its next phase of growth, the integration of advanced biotechnology and material innovation will remain central to its competitive strategy. By fostering deeper collaborations with global industrial partners and continuing to invest in its research network, Sciessent is prepared to address the evolving challenges of the textile and medical sectors, ensuring long-term value creation for its stakeholders and clients alike.
See full Sciessent company page
